Cannabis Science Inc (OTCMKTS:CBIS) took a healthy jump up 13% today. CBIS was boosted on news that hit the wire today that it was close completing its new CBD formulation for treating Asthma and COPD (Chronic Obstructive Pulmonary Disease). CBIS has been on a downward slope YTD but the stock has rallied at the end of the year – up a total of 12% since the start of September.
“This is an immense market segment, with approximately 5 million people with diagnosed cases of COPD in the United States alone and the 20 % prevalence of the Asthma, COPD Overlap Syndrome offers a known market of approximately 5 million doses per month potential for CBIS’ new formula.
Cannabis Science Inc (OTCMKTS:CBIS) defines itself according to the narrative of a leading-edge researcher and designer of cannabinoid solutions to health problems.
CBIS is involved in developing medicines for autism, blood pressure, cancer and cancer